arca biopharma inc (ABIO) Key Developments
ARCA biopharma, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 11 15
ARCA biopharma, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $2,719,000 against $2,406,000 a year ago. Net loss and comprehensive loss was $2,719,000 or $0.10 per basic and diluted share against $2,405,000 or $0.11 per basic and diluted share a year ago.
For the six months, the company reported loss from operations of $5,463,000 against $4,796,000 a year ago. Net loss and comprehensive loss was $5,463,000 or $0.22 per basic and diluted share against $4,794,000 or $0.24 per basic and diluted share a year ago.
ARCA biopharma, Inc. Regains Compliance With Minimum Bid Price Rule Of The NASDAQ Capital Market
Jul 16 15
On July 15, 2015, The Nasdaq Stock Market, notified ARCA biopharma, Inc. that the company had regained compliance with the applicable minimum bid price rule of The NASDAQ Capital Market as set forth in NASDAQ Rule 5550(a)(2). Accordingly, the previous notice received by the company on February 18, 2015 is now closed. On June 22, 2015, the company’s stockholders authorized the company’s Board of Directors for a period of up to one year, to effect a reverse split of the company’s common stock. Although the company has regained compliance with the Nasdaq listing standards, the company’s Board may still elect to proceed with the reverse split if, in the Board’s judgment, it is considered to be in the best interest of the company’s stockholders.
ARCA biopharma, Inc. Proposes Amendments to the Restated Certificate of Incorporation
Apr 14 15
ARCA biopharma, Inc. proposed to approve amendments to the Company’s restated certificate of incorporation, as amended, and authorize the Board of Directors, if in their judgment it is necessary, to select and file one such amendment to effect a reverse stock split of common stock, at a ratio in the range of 3:1 to 20:1, such ratio to be determined at the discretion of the Board of Directors, to it's annual general meeting to be held on June 04, 2015.
ARCA biopharma, Inc., Annual General Meeting, Jun 22, 2015
Apr 14 15
ARCA biopharma, Inc., Annual General Meeting, Jun 22, 2015., at 09:00 Mountain Daylight. Location: 11080 CirclePoint Road, Suite 140. Agenda: To elect the board’s nominees, Dr. Raymond L. Woosley and Mr. Dan J. Mitchell, to the board of directors to hold office until the 2018 AGM; to ratify the selection by the audit committee of the board of directors of KPMG LLP as independent registered public accounting firm of the company for its fiscal year ending December 31, 2015; to approve amendments to the company’s restated certificate of incorporation, as amended, and authorize the board of directors, if in their judgment it is necessary, to select and file one such amendment to effect a reverse stock split of common stock, at a ratio in the range of 3:1 to 20:1, such ratio to be determined at the discretion of the board of directors; and to conduct any other business properly brought before the meeting.
ARCA biopharma, Inc. Announces Investigation of Gencaro for the Prevention of Atrial Fibrillation/Atrial Flutter by U.S. Food and Drug Administration (FDA)
Apr 13 15
ARCA biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Gencaro for the prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population (heart failure patients with reduced left ventricular ejection fraction, HFREF). Gencaro is the company's investigational, pharmacologically unique beta-blocker and mild vasodilator. According to the FDA's Fast Track Guidance document, Fast Track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Gencaro is currently being evaluated as a potential treatment for atrial fibrillation in a genetically-defined heart failure (HFREF) population in GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. ARCA anticipates that enrollment of approximately 200 patients in the Phase 2B portion of the trial will be completed by the end of 2016.